J Pathol Transl Med.  2020 Jul;54(4):276-289. 10.4132/jptm.2020.04.15.

Evolving pathologic concepts of serrated lesions of the colorectum

• Kim JH
• Kang GH

• KMID: 2504558
• DOI: http://doi.org/10.4132/jptm.2020.04.15

Abstract

Here, we provide an up-to-date review of the histopathology and molecular pathology of serrated colorectal lesions. First, we introduce the updated contents of the 2019 World Health Organization classification for serrated lesions. The sessile serrated lesion (SSL) is a new diagnostic terminology that replaces sessile serrated adenoma and sessile serrated polyp. The diagnostic criteria for SSL were revised to require only one unequivocal distorted serrated crypt, which is sufficient for diagnosis. Unclassified serrated adenomas have been included as a new category of serrated lesions. Second, we review ongoing issues concerning the morphology of serrated lesions. Minor morphologic variants with distinct molecular features were recently defined, including serrated tubulovillous adenoma, mucin-rich variant of traditional serrated adenoma (TSA), and superficially serrated adenoma. In addition to intestinal dysplasia and serrated dysplasia, minimal deviation dysplasia and not otherwise specified dysplasia were newly suggested as dysplasia subtypes of SSLs. Third, we summarize the molecular features of serrated lesions. The critical determinant of CpG island methylation development in SSLs is patient age. Interestingly, there may be ethnic differences in BRAF/KRAS mutation frequencies in SSLs. The molecular pathogenesis of TSAs is divided into KRAS and BRAF mutation pathways. SSLs with MLH1 methylation can progress into favorable prognostic microsatellite instability-positive (MSI+)/CpG island methylator phenotype-positive (CIMP+) carcinomas, whereas MLH1-unmethylated SSLs and BRAF-mutated TSAs can be precursors of poor-prognostic MSI−/CIMP+ carcinomas. Finally, based on our recent data, we propose an algorithm for stratifying risk subgroups of non-dysplastic SSLs.

Keyword

Adenoma; Colonic polyps; Colorectal neoplasms; Serrated pathway; Serrated polyp

Figure

• 

  Fig. 1. Summary of changes in terminology and categorization of serrated colorectal lesions from the 4th to the 5th edition of the World Health Organization classification.

• 

  Fig. 2. Histologic features defining sessile serrated lesions (SSLs). Architecturally distorted serrated crypts defining SSLs. Although all five vertically well-sectioned crypts included in this photomicrograph show extended serration into the lower half of the crypt, crypt base serration is subtle in all the crypts. Instead, prominent dilatation or horizontal growth of the crypt base is definite in unequivocally distorted serrated crypts (red square and arrows). Note the equivocally distorted serrated crypts showing crypt branching or mild symmetrical dilatation of the crypt base (green square and arrows). These equivocal crypts must not be counted for the diagnosis of SSL.

• 

  Fig. 3. Histologic features defining traditional serrated adenomas (TSAs). (A) A low power view of a TSA showing typical histologic features. (B) Morphologic features defining TSA. Note the centrally arranged, pencillate nuclei with abundant dense eosinophilic cytoplasm. Slit-like serrations indicate sharp invaginations (arrowheads) along the flat-topped, small intestine-like luminal border (asterisks). (C, D) Ectopic crypt formation (ECF) in a TSA (C) and in a serrated tubulovillous adenoma (D). Note the small, laterally budding crypt-like structures not reaching the muscularis mucosa (arrowheads). Although ECF is one of the morphologic characteristics of TSAs, it is not exclusive to or essential for TSAs.

• 

  Fig. 4. Updated features of CpG island methylation and MLH1 alteration in the sessile serrated neoplasia pathway. (A) A sequence model of CpG island methylation and MLH1 alteration during the multistep sessile serrated lesion (SSL)-to-carcinoma pathway. Note that both MLH1 promoter methylation and CpG island methylator phenotype-positivity (CIMP+) are late-step epigenetic events during the progression of non-dysplastic SSLs, and mainly occur in proximal, large (>5 mm) SSLs in older patients (≥50 years). (B) Complete loss of MLH1 expression in an SSL with dysplasia harboring the MLH1 methylation. (C) Partial loss of MLH1 expression (involving a few non-dysplastic crypts; red ellipse) in a non-dysplastic SSL with MLH1 methylation. Modified from Lee et al. J Pathol Transl Med 2019; 53: 225-35.

• 

  Fig. 5. Serrated lesions as precursors of different molecular subtypes of colorectal carcinoma (CRC). (A) Prognostically implicated molecular subtypes of CRCs and their conceptually matched precursor lesions. SSL, sessile serrated lesion; TSA, traditional serrated adenoma; MrTSA, mucin-rich traditional serrated adenoma; USA, unclassified serrated adenoma; sTVA, serrated tubulovillous adenoma; SuSA, superficially serrated adenoma; TA, tubular adenoma; TVA, tubulovillous adenoma; VA, villous adenoma; MSI, microsatellite instability; MSI+, MSI-positive; MSI−, MSI-negative; CIMP, CpG island methylator phenotype; CIMP+, CIMP-positive; CIMP−, CIMP-negative; mt, mutant-type; wt, wild-type. (B) An example of a two-step screening algorithm to stratify the risk subgroups of non-dysplastic SSLs.

Reference

1. WHO Classification of Tumours Editorial Board. WHO classification of tumors: digestive system tumours. 5th ed. Lyon: International Agency for Research on Cancer;2019.

2. Bateman AC, Shepherd NA. UK guidance for the pathological reporting of serrated lesions of the colorectum. J Clin Pathol. 2015; 68:585–91.

3. International Agency for Research on Cancer. WHO classification of tumours of the digestive system. 4th ed. Lyon: International Agency for Research on Cancer;2010.

4. Pai RK, Bettington M, Srivastava A, Rosty C. An update on the morphology and molecular pathology of serrated colorectal polyps and associated carcinomas. Mod Pathol. 2019; 32:1390–415.

5. Rex DK, Ahnen DJ, Baron JA, et al. Serrated lesions of the colorectum: review and recommendations from an expert panel. Am J Gastroenterol. 2012; 107:1315–29.

6. Hafezi-Bakhtiari S, Wang LM, Colling R, Serra S, Chetty R. Histological overlap between colorectal villous/tubulovillous and traditional serrated adenomas. Histopathology. 2015; 66:308–13.

7. Bettington M, Walker N, Rosty C, et al. Serrated tubulovillous adenoma of the large intestine. Histopathology. 2016; 68:578–87.

8. Kalimuthu SN, Serra S, Hafezi-Bakhtiari S, Colling R, Wang LM, Chetty R. Mucin-rich variant of traditional serrated adenoma: a distinct morphological variant. Histopathology. 2017; 71:208–16.

9. Hiromoto T, Murakami T, Akazawa Y, et al. Immunohistochemical and genetic characteristics of a colorectal mucin-rich variant of traditional serrated adenoma. Histopathology. 2018; 73:444–53.

10. Hashimoto T, Tanaka Y, Ogawa R, et al. Superficially serrated adenoma: a proposal for a novel subtype of colorectal serrated lesion. Mod Pathol. 2018; 31:1588–98.

11. McCarthy AJ, Serra S, Chetty R. Traditional serrated adenoma: an overview of pathology and emphasis on molecular pathogenesis. BMJ Open Gastroenterol. 2019; 6:e000317.

12. Mizuguchi Y, Sakamoto T, Hashimoto T, et al. Identification of a novel PRR15L-RSPO2 fusion transcript in a sigmoid colon cancer derived from superficially serrated adenoma. Virchows Arch. 2019; 475:659–63.

13. Cenaj O, Gibson J, Odze RD. Clinicopathologic and outcome study of sessile serrated adenomas/polyps with serrated versus intestinal dysplasia. Mod Pathol. 2018; 31:633–42.

14. Liu C, Walker NI, Leggett BA, Whitehall VL, Bettington ML, Rosty C. Sessile serrated adenomas with dysplasia: morphological patterns and correlations with MLH1 immunohistochemistry. Mod Pathol. 2017; 30:1728–38.

15. Amin MB, Edge S, Greene F, et al. AJCC cancer staging manual. Chicago: Springer;2017.

16. Kang GH. Four molecular subtypes of colorectal cancer and their precursor lesions. Arch Pathol Lab Med. 2011; 135:698–703.

17. Bae JM, Kim JH, Kang GH. Molecular subtypes of colorectal cancer and their clinicopathologic features, with an emphasis on the serrated neoplasia pathway. Arch Pathol Lab Med. 2016; 140:406–12.

18. Kim JH, Kang GH. Molecular and prognostic heterogeneity of microsatellite-unstable colorectal cancer. World J Gastroenterol. 2014; 20:4230–43.

19. Amemori S, Yamano HO, Tanaka Y, et al. Sessile serrated adenoma/polyp showed rapid malignant transformation in the final 13 months. Dig Endoscd. 2019; Nov. 1. [Epub]. https://doi.org/10.1111/den.13572.

20. Burgess NG, Tutticci NJ, Pellise M, Bourke MJ. Sessile serrated adenomas/polyps with cytologic dysplasia: a triple threat for interval cancer. Gastrointest Endosc. 2014; 80:307–10.

21. Lee JA, Park HE, Yoo SY, et al. CpG island methylation in sessile serrated adenoma/polyp of the colorectum: implications for differential diagnosis of molecularly high-risk lesions among non-dysplastic sessile serrated adenomas/polyps. J Pathol Transl Med. 2019; 53:225–35.

22. Liu C, Bettington ML, Walker NI, et al. CpG island methylation in sessile serrated adenomas increases with age, indicating lower risk of malignancy in young patients. Gastroenterology. 2018; 155:1362–5.

23. Bettington M, Brown I, Rosty C, et al. Sessile serrated adenomas in young patients may have limited risk of malignant progression. J Clin Gastroenterol. 2019; 53:e113–6.

24. Bettington M, Walker N, Rosty C, et al. Clinicopathological and molecular features of sessile serrated adenomas with dysplasia or carcinoma. Gut. 2017; 66:97–106.

25. Yozu M, Kem M, Cenaj O, Mino-Kenudson M, Odze RD, Misdraji J. Loss of expression of MLH1 in non-dysplastic crypts is a harbinger of neoplastic progression in sessile serrated adenomas/polyps. Histopathology. 2019; 75:376–84.

26. Bettington M, Walker N, Clouston A, Brown I, Leggett B, Whitehall V. The serrated pathway to colorectal carcinoma: current concepts and challenges. Histopathology. 2013; 62:367–86.

27. O’Brien MJ, Zhao Q, Yang S. Colorectal serrated pathway cancers and precursors. Histopathology. 2015; 66:49–65.

28. Rhee YY, Kim KJ, Kang GH. CpG island methylator phenotypehigh colorectal cancers and their prognostic implications and relationships with the serrated neoplasia pathway. Gut Liver. 2017; 11:38–46.

29. Weisenberger DJ, Siegmund KD, Campan M, et al. CpG island methylator phenotype underlies sporadic microsatellite instability and is tightly associated with BRAF mutation in colorectal cancer. Nat Genet. 2006; 38:787–93.

30. Fang M, Ou J, Hutchinson L, Green MR. The BRAF oncoprotein functions through the transcriptional repressor MAFG to mediate the CpG island methylator phenotype. Mol Cell. 2014; 55:904–15.

31. Fang M, Hutchinson L, Deng A, Green MR. Common BRAF (V600E)-directed pathway mediates widespread epigenetic silencing in colorectal cancer and melanoma. Proc Natl Acad Sci U S A. 2016; 113:1250–5.

32. Tao Y, Kang B, Petkovich DA, et al. Aging-like spontaneous epigenetic silencing facilitates Wnt activation, stemness, and BRAF(V600E)- induced tumorigenesis. Cancer Cell. 2019; 35:315–28.

33. Jass JR, Baker K, Zlobec I, et al. Advanced colorectal polyps with the molecular and morphological features of serrated polyps and adenomas: concept of a 'fusion' pathway to colorectal cancer. Histopathology. 2006; 49:121–31.

34. Chung SM, Chen YT, Panczykowski A, Schamberg N, Klimstra DS, Yantiss RK. Serrated polyps with “intermediate features” of sessile serrated polyp and microvesicular hyperplastic polyp: a practical approach to the classification of nondysplastic serrated polyps. Am J Surg Pathol. 2008; 32:407–12.

35. Kim YH, Kakar S, Cun L, Deng G, Kim YS. Distinct CpG island methylation profiles and BRAF mutation status in serrated and adenomatous colorectal polyps. Int J Cancer. 2008; 123:2587–93.

36. Caruso M, Moore J, Goodall GJ, et al. Over-expression of cathepsin E and trefoil factor 1 in sessile serrated adenomas of the colorectum identified by gene expression analysis. Virchows Arch. 2009; 454:291–302.

37. Sandmeier D, Benhattar J, Martin P, Bouzourene H. Serrated polyps of the large intestine: a molecular study comparing sessile serrated adenomas and hyperplastic polyps. Histopathology. 2009; 55:206–13.

38. Yachida S, Mudali S, Martin SA, Montgomery EA, Iacobuzio-Donahue CA. Beta-catenin nuclear labeling is a common feature of sessile serrated adenomas and correlates with early neoplastic progression after BRAF activation. Am J Surg Pathol. 2009; 33:1823–32.

39. Mesteri I, Bayer G, Meyer J, et al. Improved molecular classification of serrated lesions of the colon by immunohistochemical detection of BRAF V600E. Mod Pathol. 2014; 27:135–44.

40. Rau TT, Agaimy A, Gehoff A, et al. Defined morphological criteria allow reliable diagnosis of colorectal serrated polyps and predict polyp genetics. Virchows Arch. 2014; 464:663–72.

41. Rau TT, Atreya R, Aust D, et al. Inflammatory response in serrated precursor lesions of the colon classified according to WHO entities, clinical parameters and phenotype-genotype correlation. J Pathol Clin Res. 2016; 2:113–24.

42. Fujita K, Yamamoto H, Matsumoto T, et al. Sessile serrated adenoma with early neoplastic progression: a clinicopathologic and molecular study. Am J Surg Pathol. 2011; 35:295–304.

43. Kim KM, Lee EJ, Ha S, et al. Molecular features of colorectal hyperplastic polyps and sessile serrated adenoma/polyps from Korea. Am J Surg Pathol. 2011; 35:1274–86.

44. Maeda T, Suzuki K, Togashi K, et al. Sessile serrated adenoma shares similar genetic and epigenetic features with microsatellite unstable colon cancer in a location-dependent manner. Exp Ther Med. 2011; 2:695–700.

45. Kwon HJ, Cho NY, Chang MS, Kim YS, Kang GH. Intermediate serrated polyp as an intermediate lesion of hyperplastic polyp and sessile serrated polyp/adenoma in terms of morphological and molecular features. Hum Pathol. 2014; 45:1759–65.

46. Morimoto T, Mitomi H, Saito T, et al. Distinct profile of HIF1α, PTCH, EphB2, or DNA repair protein expression and BRAF mutation in colorectal serrated adenoma. J Gastroenterol Hepatol. 2014; 29:1192–9.

47. Naito T, Nosho K, Ito M, et al. IGF2 differentially methylated region hypomethylation in relation to pathological and molecular features of serrated lesions. World J Gastroenterol. 2014; 20:10050–61.

48. Qiu Y, Fu X, Zhang W, et al. Prevalence and molecular characterisation of the sessile serrated adenoma in a subset of the Chinese population. J Clin Pathol. 2014; 67:491–8.

49. Lee H, Lee JH, Kim DK, et al. PIK3CA amplification is common in left side-tubular adenomas but uncommon sessile serrated adenomas exclusively with KRAS mutation. Int J Med Sci. 2015; 12:349–53.

50. Murakami T, Mitomi H, Saito T, et al. Distinct WNT/beta-catenin signaling activation in the serrated neoplasia pathway and the adenoma-carcinoma sequence of the colorectum. Mod Pathol. 2015; 28:146–58.

51. Nosho K, Igarashi H, Ito M, et al. Clinicopathological and molecular characteristics of serrated lesions in Japanese elderly patients. Digestion. 2015; 91:57–63.

52. Tanaka Y, Yamano HO, Yamamoto E, et al. Endoscopic and molecular characterization of colorectal sessile serrated adenoma/polyps with cytologic dysplasia. Gastrointest Endosc. 2017; 86:1131–8.

53. Hashimoto T, Yamashita S, Yoshida H, et al. WNT pathway gene mutations are associated with the presence of dysplasia in colorectal sessile serrated adenoma/polyps. Am J Surg Pathol. 2017; 41:1188–97.

54. Cho H, Hashimoto T, Yoshida H, et al. Reappraisal of the genetic heterogeneity of sessile serrated adenoma/polyp. Histopathology. 2018; 73:672–80.

55. Chan AW, Pan Y, Tong JH, et al. Receptor tyrosine kinase fusions act as a significant alternative driver of the serrated pathway in colorectal cancer development. J Pathol. 2020; 251:74–86.

56. Mochizuka A, Uehara T, Nakamura T, Kobayashi Y, Ota H. Hyperplastic polyps and sessile serrated ‘adenomas’ of the colon and rectum display gastric pyloric differentiation. Histochem Cell Biol. 2007; 128:445–55.

57. Fujita K, Hirahashi M, Yamamoto H, et al. Mucin core protein expression in serrated polyps of the large intestine. Virchows Arch. 2010; 457:443–9.

58. Gibson JA, Hahn HP, Shahsafaei A, Odze RD. MUC expression in hyperplastic and serrated colonic polyps: lack of specificity of MUC6. Am J Surg Pathol. 2011; 35:742–9.

59. Gonzalo DH, Lai KK, Shadrach B, et al. Gene expression profiling of serrated polyps identifies annexin A10 as a marker of a sessile serrated adenoma/polyp. J Pathol. 2013; 230:420–9.

60. Delker DA, McGettigan BM, Kanth P, et al. RNA sequencing of sessile serrated colon polyps identifies differentially expressed genes and immunohistochemical markers. PLoS One. 2014; 9:e88367.

61. Kim JH, Kim KJ, Rhee YY, et al. Gastric-type expression signature in serrated pathway-associated colorectal tumors. Hum Pathol. 2015; 46:643–56.

62. Rickelt S, Condon C, Mana M, et al. Agrin in the muscularis mucosa serves as a biomarker distinguishing hyperplastic polyps from sessile serrated lesions. Clin Cancer Res. 2020; 26:1277–87.

63. Tsai JH, Liau JY, Lin YL, et al. Traditional serrated adenoma has two pathways of neoplastic progression that are distinct from the sessile serrated pathway of colorectal carcinogenesis. Mod Pathol. 2014; 27:1375–85.

64. Bettington ML, Walker NI, Rosty C, et al. A clinicopathological and molecular analysis of 200 traditional serrated adenomas. Mod Pathol. 2015; 28:414–27.

65. Kim MJ, Lee EJ, Suh JP, et al. Traditional serrated adenoma of the colorectum: clinicopathologic implications and endoscopic findings of the precursor lesions. Am J Clin Pathol. 2013; 140:898–911.

66. Chetty R, Hafezi-Bakhtiari S, Serra S, Colling R, Wang LM. Traditional serrated adenomas (TSAs) admixed with other serrated (socalled precursor) polyps and conventional adenomas: a frequent occurrence. J Clin Pathol. 2015; 68:270–3.

67. Hashimoto T, Ogawa R, Yoshida H, et al. Acquisition of WNT pathway gene alterations coincides with the transition from precursor polyps to traditional serrated adenomas. Am J Surg Pathol. 2019; 43:132–9.

68. Borowsky J, Dumenil T, Bettington M, et al. The role of APC in WNT pathway activation in serrated neoplasia. Mod Pathol. 2018; 31:495–504.

69. Sekine S, Yamashita S, Tanabe T, et al. Frequent PTPRK-RSPO3 fusions and RNF43 mutations in colorectal traditional serrated adenoma. J Pathol. 2016; 239:133–8.

70. Sekine S, Ogawa R, Hashimoto T, et al. Comprehensive characterization of RSPO fusions in colorectal traditional serrated adenomas. Histopathology. 2017; 71:601–9.

71. Tsai JH, Liau JY, Yuan CT, et al. RNF43 is an early and specific mutated gene in the serrated pathway, with increased frequency in traditional serrated adenoma and its associated malignancy. Am J Surg Pathol. 2016; 40:1352–9.

72. Hashimoto T, Ogawa R, Yoshida H, et al. EIF3E-RSPO2 and PIEZO1-RSPO2 fusions in colorectal traditional serrated adenoma. Histopathology. 2019; 75:266–73.

73. Sohier P, Sanson R, Leduc M, et al. Proteome analysis of formalinfixed paraffin-embedded colorectal adenomas reveals the heterogeneous nature of traditional serrated adenomas compared to other colorectal adenomas. J Pathol. 2020; 250:251–61.

74. Phipps AI, Limburg PJ, Baron JA, et al. Association between molecular subtypes of colorectal cancer and patient survival. Gastroenterology. 2015; 148:77–87.

75. Phipps AI, Alwers E, Harrison T, et al. Association between molecular subtypes of colorectal tumors and patient survival, based on pooled analysis of 7 international studies. Gastroenterology. 2020; 158:2158–68.

76. Kim JH, Bae JM, Cho NY, Kang GH. Distinct features between MLH1-methylated and unmethylated colorectal carcinomas with the CpG island methylator phenotype: implications in the serrated neoplasia pathway. Oncotarget. 2016; 7:14095–111.